Involvement of FcγR I (CD64) in the Mechanism of HIV-1 Inhibition by Polyclonal IgG Purified from Infected Patients in Cultured Monocyte-Derived Macrophages-Reference-Cited by-同舟云学术

Involvement of FcγR I (CD64) in the Mechanism of HIV-1 Inhibition by Polyclonal IgG Purified from Infected Patients in Cultured Monocyte-Derived Macrophages

Published:2004-11-04 Issue:10 Volume:173 Page:6274-6283
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Holl Vincent,Hemmerter Stéphane,Burrer Renaud,Schmidt Sylvie,Bohbot Alain,Aubertin Anne-Marie,Moog Christiane

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference48 articles.

1. Ho, D. D. 1998. Toward HIV eradication or remission: the tasks ahead. Science 2801866.

2. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus

3. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir

4. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy

5. Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14 + Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recombinant factor VIII Fc fusion protein engages monocytes via Fc and FVIII domains to reduce monocyte differentiation into osteoclasts;Frontiers in Hematology;2022-11-03

2. Distinct antibody profiles in HLA-B*57 + , HLA-B*57 - HIV controllers and chronic progressors;AIDS;2021-10-01

3. Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01;Frontiers in Immunology;2021-08-31

4. A new lease on life for an HIV-neutralizing antibody class and vaccine target;Proceedings of the National Academy of Sciences;2021-01-27

5. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy;Theranostics;2021